Bronchopulmonary Dysplasia Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

BPD is a chronic lung disorder primarily affecting premature infants who require prolonged mechanical ventilation or oxygen therapy. The global market for BPD treatment and management was valued at roughly $3.25 billion in 2025 and is expanding at a compound annual growth rate near 5.4%. It encompasses drugs, respiratory support products, and adjunctive therapies used in neonatal intensive care units worldwide.

• •Valued at ~$3.25 billion in 2025 with a 5.4% CAGR through the forecast period
• •Driven by a steady rise in preterm birth rates globally
• •Includes pharmacologic agents, biologics, and respiratory support interventions

Increasing survival rates of extremely preterm infants are creating a larger addressable patient pool requiring BPD-related therapies. Improved neonatal ventilation techniques and the development of targeted pharmacologic options, including corticosteroids and pulmonary vasodilators, are also accelerating market growth. Rising healthcare expenditure in emerging economies is expanding access to advanced neonatal care.

• •Higher survival of extremely preterm infants increases BPD incidence and treatment demand
• •Advances in neonatal pharmacology and respiratory support technology
• •Expanding NICU infrastructure in Asia-Pacific and Latin America

The market is commonly segmented by drug class (such as corticosteroids, bronchodilators, diuretics, and pulmonary vasodilators), by distribution channel (hospitals, specialty clinics, and retail pharmacies), and by geography. North America currently holds the largest share due to advanced neonatal care systems and high healthcare spending, while Asia-Pacific is expected to record the fastest growth on the back of improving perinatal care.

• •Drug-class segmentation includes corticosteroids, diuretics, bronchodilators, and pulmonary vasodilators
• •Hospitals and NICUs account for the dominant share of distribution
• •Asia-Pacific is forecast to be the fastest-growing regional market

What are the recent trends and outlook?

The BPD market is shifting toward precision neonatal medicine, with growing interest in biomarkers, stem-cell-based interventions, and anti-inflammatory biologics tailored to preterm lung injury. Regulatory agencies are encouraging pediatric drug development through priority review pathways, which is expected to bring more targeted therapies to market. Over the forecast period, demand for less invasive ventilation strategies and disease-modifying treatments is likely to reshape clinical practice.

• •Pipeline activity in stem-cell therapies and biologics for neonatal lung injury
• •Regulatory incentives accelerating pediatric and neonatal drug approvals
• •Shift toward less invasive respiratory support and personalized treatment approaches